HomeAI · summaries
Storia in 11 fonti
AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs
AbbVie’s largest deal in more than half a decade adds a group of immune disease medications — among them a Dupixent competitor — the company believes to have “mega-blockbuster” sales potential.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
markets.businessinsider.com
M&A News: AbbVie Lining up an $11B Deal for Eczema Drug Maker Apogee Therapeutics
Shares in biotechnology company Apogee Therapeutics (APGE) are set to start the new week off in great shape on reports that it could be swallowe...
- ·
wiwo.de
Pharmaindustrie: AbbVie wohl vor Übernahme von Biotechfirma Apogee Therapeutics
Der Pharmariese aus den USA plant offenbar den Kauf von Apogee Therapeutics. Das Angebot stellt einen deutlichen Aufschlag dar.
